People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

Improvement seen in resolution of steatohepatitis without worsening of fibrosis and in fibrosis without worsening of steatohepatitis. (HealthDay News) — For patients with metabolic dysfunction ...

Semaglutide shows promise in MASH treatment, achieving significant MASH resolution and fibrosis improvement in the ESSENCE trial. Tolerability issues and insurance coverage challenges lead to 20% ...

The data will further extend the wide-ranging evidence base for semaglutide through real-world evidence studies and additional analysis of the landmark cardiovascular outcomes trial, SELECT ...

I read with interest about the “middle-class microdoser” of the weight-loss drug Wegovy, who lost 20 kilograms of body weight over nine months. That is a long time to be eating less than his ...

Maybe you’ve used compounded IV medications at a medical spa. In any case, share your story with us so we can learn more.

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

They’re heading in droves to health and spa hotels in India and Sri Lanka, or to new retreats founded on Ayurvedic principles everywhere from Tuscany to Mallorca. As a city we’re no strangers to ...

First off, it’s important to note that the moniker is misleading. Ozempic, a specific brand of the drug semaglutide, often gets used as the shorthand for all GLP-1s – primarily because it’s ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...